Screener
TransMedics Group, Inc. TMDX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206453
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash | $461,739 | $488,366 |
| Accounts receivable | 90,727 | 84,282 |
| Inventory | 49,890 | 48,881 |
| Prepaid expenses and other current assets | 16,924 | 16,254 |
| Total current assets | 619,280 | 637,783 |
| Property, plant and equipment, net | 361,571 | 327,656 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is TransMedics Group, Inc.'s cash & equivalents?
- TransMedics Group, Inc. (TMDX) reported cash & equivalents of $461.74M in Q1 2026.
- How has TransMedics Group, Inc.'s cash & equivalents changed year-over-year?
- TransMedics Group, Inc.'s cash & equivalents increased by 48.9% year-over-year, from $310.14M to $461.74M.
- What is the long-term trend for TransMedics Group, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), TransMedics Group, Inc.'s cash & equivalents has grown at a 81.8% compound annual growth rate (CAGR), from $24.58M to $488.37M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about TransMedics Group, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude